Skip to main content

Bioxcel Therapeutics Inc(BTAI-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Bioxcel Therapeutics Inc

555 LONG WHARF DRIVE
NEW HAVEN CT 06511 USA
P: 475-238-6837
http://www.bioxceltherapeutics.com

Profile

BioXcel Therapeutics Inc. is a clinical stage biopharmaceutical company. It focuses on drug development which utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's product portfolio include BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. BioXcel Therapeutics Inc. is based in the United States.

Key Executives

NameTitle
Richard I. SteinhartCFO/Chief Accounting Officer/Senior VP
Vincent J. O'NeillChief Medical Officer/Executive VP/Other Executive Officer
Vimal MehtaCEO/Co-Founder/Director/President
Frank D. YoccaChief Scientific Officer/Senior VP
Matthew T. WileyOther Executive Officer/Senior VP
Javier RodriguezChief Legal Officer/Secretary/Senior VP

More from The Globe